AbbVie's oral upadacitinib, or ABT-494, met the primary endpoint of a late-stage trial for patients with moderate to severe rheumatoid arthritis, achieving 20% improvement of a significantly higher portion of patients receiving once-daily 15- and 30-mg doses of the drug at week 12 compared with placebo. The drug also met the secondary endpoint of the study, in which a significantly greater proportion of patients who received both doses of upadacitinib experienced low disease activity at week 12 versus placebo use.
AbbVie reports positive results from Phase III RA study
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.